SANTA BARBARA, Calif. - Bruker (NASDAQ:BRKR) Corporation (NASDAQ:BRKR) today unveiled the Dimension Nexus atomic force microscope (AFM), a new addition to its Dimension AFM product line, at the 2024 MRS Fall Meeting & Exhibit. The Dimension Nexus is designed to offer a combination of performance and value for growing labs and multi-user facilities.
The Dimension Nexus features the latest-generation NanoScope 6 controller and provides access to over 50 AFM modes, including Bruker’s exclusive PeakForce Tapping technology. This technology is expected to benefit a wide range of research applications due to its compact, upgradable design and the system’s capacity for large-sample analysis.
Dr. Alice Pyne, Head of the Henry Royce Nanocharacterisation Laboratory at the University of Sheffield, noted the system’s potential for facilities that accommodate a diverse range of research needs and where space for instruments is limited.
Thomas Mueller, Senior Director of AFM Instrumentation at Bruker, emphasized that the new AFM aims to make advanced AFM technology more accessible to the broader research community. He highlighted the system's data quality, performance, and versatility as key features that make it suitable for both new and established AFM labs.
The Dimension Nexus is reported to have an open-architecture system with low drift and low noise, which allows for high-quality data collection in both standard and custom experiments. The NanoScope 6 controller is designed to facilitate ease of use, while the programmable stage supports high-throughput multi-site analysis. The system also supports a range of unique modes for specialized measurements.
Bruker Corporation, known for its contributions to post-genomic era scientific advancements, provides instruments and solutions that enable detailed exploration of life and materials at various scales. The company's offerings span across life science molecular and cell biology research, applied and biopharma applications, microscopy, nanoanalysis, industrial and cleantech research, and semiconductor metrology. Currently trading at $57.95, between its 52-week range of $48.07 to $94.86, the stock appears slightly overvalued according to InvestingPro Fair Value metrics. Investors seeking detailed analysis can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, which covers over 1,400 US stocks including BRKR.
This news is based on a press release statement from Bruker Corporation. For investors interested in deeper financial analysis, InvestingPro offers additional insights, including multiple ProTips and extensive financial metrics that highlight the company's strong cash flows and profitability status.
In other recent news, Bruker Corporation witnessed a year-over-year revenue increase of 16.4% in its third quarter of 2024, amounting to $864.4 million. This growth has been credited to both organic growth and the impact of recent acquisitions. However, despite the upward trend, the company has revised its full-year 2024 guidance downwards due to slower recoveries in the biopharma sector and Chinese market demand. The non-GAAP diluted EPS for Q3 was reported at $0.60, marking a decrease from the previous year's $0.74.
The company anticipates a muted recovery in 2025, with normalized market growth rates expected by 2026. Bruker's management is aiming for a break-even point for the NanoString and Cellular Analysis businesses by 2026 and expects significant margin improvements over the next three years. The company's outlook remains cautiously optimistic, focusing on operational improvements and innovation in diagnostics and semiconductor metrology.
These are recent developments for Bruker, which has reported strong demand in diagnostics and semiconductor metrology. However, the company's recovery in the biopharma sector and orders from China are not expected to materialize in 2024. Despite these challenges, Bruker remains committed to its growth strategy and operational improvements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.